Shreyas Joshi

1 week ago | urologytimes.com | Mark Tyson |Trinity J. Bivalacqua |Shreyas Joshi |Bogdana Schmidt

Author(s):,Panelists discuss evolving strategies for managing non–muscle-invasive bladder cancer (NMIBC), highlighting how risk stratification, resource limitations, and emerging therapies like gemcitabine-docetaxel are shaping treatment decisions, while emphasizing the urgent need for predictive tools and biomarkers to guide personalized care. The current standard of care for non–muscle-invasive bladder cancer (NMIBC) is highly dependent on risk stratification.

1 week ago | urologytimes.com | Mark Tyson |Trinity J. Bivalacqua |Shreyas Joshi |Bogdana Schmidt

Author(s):,Panelists discuss how the ongoing BCG shortage has forced clinicians to adapt treatment strategies for non–muscle-invasive bladder cancer (NMIBC), balancing resource constraints with patient outcomes through dose adjustments, chemotherapy substitution, and earlier cystectomy, while emphasizing the importance of maintaining trial eligibility and adhering as closely as possible to evidence-based protocols.